Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2011 (2011), Article ID 618757, 9 pages
http://dx.doi.org/10.4061/2011/618757
Research Article

17α-Ethynyl-5α-androstane-3α, 17β-diol Treatment of MNU-Induced Mammary Cancer in Rats

1Harbor BioSciences, Inc., 9171 Towne Centre Drive, Suite 180, San Diego, CA 92122, USA
2Center of Excellence in Cancer Research, Department of Biomedical Sciences, Texas Tech University Health Sciences Center, 4800 Alberta Ave, El Paso, TX 79905, USA

Received 30 October 2010; Accepted 6 January 2011

Academic Editor: Debra A. Tonetti

Copyright © 2011 Clarence N. Ahlem et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. W. Kurian, C. A. Clarke, and R. W. Carlson, “The decline in breast cancer incidence: real or imaginary?” Current Oncology Reports, vol. 11, no. 1, pp. 21–28, 2009. View at Google Scholar · View at Scopus
  2. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M. J. Thun, “Cancer statistics, 2007,” CA Cancer Journal for Clinicians, vol. 57, no. 1, pp. 43–66, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Leris and K. Mokbel, “The prevention of breast cancer: an overview,” Current Medical Research and Opinion, vol. 16, no. 4, pp. 252–257, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Sehdev, G. Martin, L. Sideris, W. Lam, and S. Brisson, “Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer,” Current Oncology, vol. 16, supplement 2, pp. S14–S23, 2009. View at Google Scholar
  5. N. Normanno, M. Di Maio, E. De Maio et al., “Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer,” Endocrine-Related Cancer, vol. 12, no. 4, pp. 721–747, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. I. Barone, L. Brusco, and S. A. W. Fuqua, “Estrogen receptor mutations and changes in downstream gene expression and signaling,” Clinical Cancer Research, vol. 16, no. 10, pp. 2702–2708, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. D. J. Bentrem and V. C. Jordan, “Targeted antiestrogens for the prevention of breast cancer,” Oncology Research, vol. 11, no. 9, pp. 401–407, 1999. View at Google Scholar · View at Scopus
  8. B. A. Gusterson and J. C. Williams, “N-nitrosomethylurea-induced rat mammary tumours as models of human breast cancer,” Journal of the Royal Society of Medicine, vol. 74, no. 1, pp. 56–59, 1981. View at Google Scholar · View at Scopus
  9. D. Medina, “Chemical carcinogenesis of rat and mouse mammary glands,” Breast Disease, vol. 28, pp. 63–68, 2007. View at Google Scholar · View at Scopus
  10. R. Trauger, E. Corey, D. Bell et al., “Inhibition of androstenediol-dependent LNCaP tumour growth by 17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235),” British Journal of Cancer, vol. 100, no. 7, pp. 1068–1072, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. T. D. Koreckij, R. J. Trauger, R. B. Montgomery et al., “HE3235 inhibits growth of castration-resistant prostate cancer,” Neoplasia, vol. 11, no. 11, pp. 1216–1225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Ahlem, M Kennedy, T. Page et al., “17alpha-Alkynyl-3alpha, 17beta-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism,” Investigational New Drugs. In press.
  13. D. L. McCormick, C. B. Adamowski, A. Fiks, and R. C. Moon, “Lifetime dose-response relationships for mammary tumor induction by a single administration of N-methyl-N-nitrosourea,” Cancer Research, vol. 41, no. 5, pp. 1690–1694, 1981. View at Google Scholar · View at Scopus
  14. L. Rajkumar, R. C. Guzman, J. Yang, G. Thordarson, F. Talamantes, and S. Nandi, “Short-term exposure to pregnancy levels of estrogen prevents mammary carcinogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 20, pp. 11755–11759, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. E. R. DeSombre and L. Y. Arbogast, “Effect of the antiestrogen C1628 on the growth of rat mammary tumors,” Cancer Research, vol. 34, no. 8, pp. 1971–1976, 1974. View at Google Scholar · View at Scopus
  16. P. D. Siebert and A. Chenchik, “Modified acid guanidinium thiocyanate-phenol- chloroform RNA extraction method which greatly reduces DNA contamination,” Nucleic Acids Research, vol. 21, no. 8, pp. 2019–2020, 1993. View at Google Scholar · View at Scopus
  17. H. Engel, C. Kueppers, M. Koenig, and D. Loeffert, “Successful gene expression analysis by multiplex, real-time, one-step RT-PCR, irrespective of the targets amplified,” BioTechniques, vol. 43, no. 2, pp. 230–231, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. G. J. Kelloff, R. A. Lubet, R. Lieberman et al., “Aromatase inhibitors as potential cancer chemopreventives,” Cancer Epidemiology Biomarkers and Prevention, vol. 7, no. 1, pp. 65–78, 1998. View at Google Scholar · View at Scopus
  19. T. Jackson, L. W. L. Woo, M. N. Trusselle et al., “Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity,” Organic and Biomolecular Chemistry, vol. 5, no. 18, pp. 2940–2952, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. R. Sharma, R. P. Kline, ED. X. Wu, and J. K. Katz, “Rapid in vivo Taxotere quantitative chemosensitivity response by 4.23 Tesla sodium MRI and histo-immunostaining features in N-Methyl-N-Nitrosourea induced breast tumors in rats,” Cancer Cell International, vol. 5, article26, 2005. View at Publisher · View at Google Scholar · View at PubMed
  21. P. E. Goss, K. Strasser-Weippl, S. Qi, and H. Hu, “Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model,” BMC Cancer, vol. 7, article 26, 2007. View at Publisher · View at Google Scholar · View at PubMed
  22. M. Smollich, M. Götte, J. Fischgräbe, I. Radke, L. Kiesel, and P. Wülfing, “Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells,” Anticancer Research, vol. 29, no. 6, pp. 2167–2171, 2009. View at Google Scholar · View at Scopus
  23. S. De, R. Cipriano, M. W. Jackson, and G. R. Stark, “Overexpression of kinesins mediates docetaxel resistance in breast cancer cells,” Cancer Research, vol. 69, no. 20, pp. 8035–8042, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. M. Razandi, A. Pedram, and E. R. Levin, “Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer,” Molecular Endocrinology, vol. 14, no. 9, pp. 1434–1447, 2000. View at Google Scholar · View at Scopus
  25. A. Marwah, P. Marwah, and H. Lardy, “Ergosteroids—6. Metabolism of dehydroepiandrosterone by rat liver in vitro: a liquid chromatographic-mass spectrometric study,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 767, no. 2, pp. 285–299, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. O. T. Wolf and C. Kirschbaum, “Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans,” Brain Research Reviews, vol. 30, no. 3, pp. 264–288, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. E. A. Musgrove and R. L. Sutherland, “Biological determinants of endocrine resistance in breast cancer,” Nature Reviews Cancer, vol. 9, no. 9, pp. 631–643, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. T. L. Lash, M. P. Fox, J. L. Westrup, A. K. Fink, and R. A. Silliman, “Adherence to tamoxifen over the five-year course,” Breast Cancer Research and Treatment, vol. 99, no. 2, pp. 215–220, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. A. Veronesi, M. A. Pizzichetta, M. A. Ferlante et al., “Tamoxifen as adjuvant after surgery for breast cancer and tamoxifen or placebo as chemoprevention in healthy women: different compliance with treatment,” Tumori, vol. 84, no. 3, pp. 372–375, 1998. View at Google Scholar · View at Scopus
  30. S. Gangadhara and G. Bertelli, “Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women,” Therapeutics and Clinical Risk Management, vol. 5, no. 4, pp. 291–300, 2009. View at Google Scholar · View at Scopus
  31. R. Eastell, R. A. Hannon, J. Cuzick, M. Dowsett, G. Clack, and J. E. Adams, “Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230),” Journal of Bone and Mineral Research, vol. 21, no. 8, pp. 1215–1223, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. L. Ye, S. M. Bokobza, and W. G. Jiang, “Bone morphogenetic proteins in development and progression of breast cancer and therapeutic potential (review),” International Journal of Molecular Medicine, vol. 24, no. 5, pp. 591–597, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. S. E. Jones, M. A. Savin, F. A. Holmes et al., “Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer,” Journal of Clinical Oncology, vol. 24, no. 34, pp. 5381–5387, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus